Stockreport

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025 [Yahoo! Finance]

Immuneering Corporation - Class A  (IMRX) 
PDF IMM-1-104, a potential treatment for pancreatic cancer, in early January 2025. The presentation will include additional data on the combination of IMM-1-104 with other t [Read more]